The Dynamics of Chronic Gout Treatment: Medication Gaps and Return to Therapy

Meyers Primary Care Institute, Worcester, Mass., USA.
The American journal of medicine (Impact Factor: 5.3). 01/2010; 123(1):54-9. DOI: 10.1016/j.amjmed.2009.05.026
Source: PubMed

ABSTRACT To identify gaps in therapy with urate-lowering drugs for the treatment of gout as well as factors associated with resuming therapy.
From 2 integrated delivery systems, we identified patients 18 years or older with a diagnosis of gout who initiated use of a urate-lowering drug from January 1, 2000 through June 30, 2006 and who had a gap in therapy. A gap was defined as a period of over 60 days after the completion of 1 prescription in which no refill for a urate-lowering drug was obtained. Survival curves were used to assess return to therapy of urate-lowering drugs. Cox proportional hazards analysis estimated the association between covariates and return to therapy.
There were 4166 new users of urate-lowering drugs (97% received allopurinol), of whom 2929 (70%) had a gap in therapy. Among those with a gap, in 75% it occurred in the first year of therapy. Fifty percent of patients with a gap returned to therapy within 8 months, and by 4 years it was 75%. Age 45-74 years (<45 referent) and greater duration of urate-lowering drug use before the gap was associated with resuming treatment within 1 year. In contrast, receipt of nonsteroidal anti-inflammatory drugs or glucocorticoids in the year before the gap was associated with a reduced likelihood of resuming therapy.
The majority of gout patients with gaps in urate-lowering drug use returned to treatment. More investigation is needed to better understand why patients may go for months without refilling prescriptions, given the clinical consequences of nonadherence.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background For patients to effectively manage gout, they need to be aware of the impact of diet, alcohol use, and medications on their condition. We sought to examine patients’ knowledge and beliefs concerning gout and its treatment in order to identify barriers to optimal patient self-management. Methods We identified patients (≥18 years of age) cared for in the setting of a multispecialty group practice with documentation of at least one health care encounter associated with a gout diagnosis during the period 2008–2009 (n = 1346). Patients were sent a questionnaire assessing knowledge with regard to gout, beliefs about prescription medications used to treat gout, and trust in the physician. Administrative electronic health records were used to identify prescription drug use and health care utilization. Results Two hundred and forty patients returned surveys out of the 500 contacted for participation. Most were male (80%), white (94%), and aged 65 and older (66%). Only 14 (6%) patients were treated by a rheumatologist. Only a minority of patients were aware of common foods known to trigger gout (e.g., seafood [23%], beef [22%], pork [7%], and beer [43%]). Of those receiving a urate-lowering medication, only 12% were aware of the short-term risks of worsening gout with initiation. These deficits were more common in those with active as compared to inactive gout. Conclusion Knowledge deficits about dietary triggers and chronic medications were common, but worse in those with active gout. More attention is needed on patient education on gout and self-management training.
    BMC Musculoskeletal Disorders 09/2012; 13(1):180. DOI:10.1186/1471-2474-13-180 · 1.90 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Gout is crystal-induced arthritis with hyperuricemia. Uric acid lowering agent (UALA) is the maintenance drug of its treatment. Drug adherence is an important factor that influences treatment outcome. The purpose this study was to examine the drug adherence to UALA of 303 gouty patients and to analyze the factors associated with compliance.
    The Journal of the Korean Rheumatism Association 01/2010; 17(2). DOI:10.4078/jkra.2010.17.2.162
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Recent data suggesting the growing problem of medication non-adherence in gout has called for the need to synthesize the burden, determinants, and impacts of the problem. Our objective was to a conduct a systematic review of the literature examining medication adherence among patients with gout in real-world settings. Methods: We conducted a search of Medline, Embase, International Pharmaceutical Abstracts, PsycINFO, and CINAHL databases and selected studies of gout patients and medication adherence in real-world settings. We extracted information on study design, sample size, length of follow-up, data source (e.g. prescription records vs. electronic monitoring vs. self-report), type of non-adherence problem evaluated, adherence measures and reported estimates, and determinants of adherence reported in multivariable analyses. Results: We included 16 studies, which we categorized according to methods used to measure adherence including electronic prescription records (10), clinical records (1), electronic monitoring devices (1), and self-report (4). The burden of non-adherence was reported in all studies and among studies based on electronic prescription records, adherence rates were all below 0.80 and the proportion of adherent patients ranged from 10% to 46%. Six studies reported on determinants, with older age and having comorbid hypertension consistently shown to be positively associated with better adherence. One study showed the impact of adherence on achieving serum uric acid target. Conclusions: With less than half of gout patients in real-world settings adherent with their treatment, this systematic review highlights the importance of discussing adherence with medications during health care professional encounters with patients. © 2014 American College of Rheumatology.
    10/2014; 66(10). DOI:10.1002/acr.22336

Full-text (2 Sources)

Available from
Jun 1, 2014